Skip to content

Maimonides: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

Maimonides

BE 0721.607.447
NACE 46.460, Wholesale of pharmaceutical and medical goods
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
-€17,182
2024 · -€9,497-€7,685
Equity
-€63,162
2024 · -€45,981-€17,182
Cash
€0
2024 · €1-€1
Balance sheet total
€142
2024 · €381-€239

Largest movements

2024 to 2025
Assets
  • Receivables within one year -€239

    down €239 (-62.7%), from €381 to €142

Equity and liabilities
  • Other debts +€18,750

    up €18,750 (+42.6%), from €44,006 to €62,755

  • Profit (loss) carried forward -€17,182

    down €17,182 (-29.6%), from -€57,981 to -€75,162

  • Trade debts -€1,807

    down €1,807 (-76.7%), from €2,356 to €549

Income statement
  • Gross operating margin -€7,700

    down €7,700 (-90.3%), from -€8,523 to -€16,223

  • Other operating charges -€171

    down €171 (-24.3%), from €705 to €534

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 -€9,497
Gross operating margin -€7,700
Other operating charges +€171
Financial charges -€156
Result 2025 -€17,182

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations -€1
Investment €0
Financing €0
Cash 2024 €1
Net result for the year -€17,182
Receivables within one year +€239
Trade debts -€1,807
Other debts +€18,750
Cash 2025 €0
Every line side by side 23 lines
Line Code 2024 2025 Change %
Total assets 20/58 €381 €142 -€239 -62.8%
Current assets 29/58 €381 €142 -€239 -62.8%
Amounts receivable within one year 40/41 €381 €142 -€239 -62.7%
Other amounts receivable 41 €381 €142 -€239 -62.7%
Cash at bank and in hand 54/58 €1 €0 -€1 -89.9%
Total equity and liabilities 10/49 €381 €142 -€239 -62.8%
Equity 10/15 -€45,981 -€63,162 -€17,182 -37.4%
Contributions 10/11 €12,000 €12,000 = 0.0%
Profit (loss) carried forward 14 -€57,981 -€75,162 -€17,182 -29.6%
Amounts payable 17/49 €46,362 €63,304 +€16,942 +36.5%
Amounts payable within one year 42/48 €46,362 €63,304 +€16,942 +36.5%
Trade debts 44 €2,356 €549 -€1,807 -76.7%
Suppliers 440/4 €2,356 €549 -€1,807 -76.7%
Other amounts payable 47/48 €44,006 €62,755 +€18,750 +42.6%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €0 - =
Other operating charges 640/8 €705 €534 -€171 -24.3%
Gross operating margin 9900 -€8,523 -€16,223 -€7,700 -90.3%
Operating profit (loss) 9901 -€9,228 -€16,758 -€7,529 -81.6%
Financial charges 65/66B €268 €424 +€156 +58.1%
Recurring financial charges 65 €268 €424 +€156 +58.1%
Profit (loss) for the period before taxes 9903 -€9,497 -€17,182 -€7,685 -80.9%
Profit (loss) for the period 9904 -€9,497 -€17,182 -€7,685 -80.9%
Profit (loss) for the period to be appropriated 9905 -€9,497 -€17,182 -€7,685 -80.9%

Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 4 October 2026 via checked.be.